Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17. https://doi.org/10.1176/AJP.2006.163.11.1905/ASSET/IMAGES/R114F4.JPEG.

Article  PubMed  Google Scholar 

Zvozilova A, Bukatova S, Koprdova R, Mach M. Evaluation of new approaches to depression treatment using an animal model of pharmacoresistant depression. Int J Mol Sci. 2024;25:5265. https://doi.org/10.3390/IJMS25105265.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gałecki P, Bliźniewska-Kowalska K. Treatment-resistant depression - recommendations of the national consultant in the field of psychiatry. Psychiatr Pol. 2021;55:7–21. https://doi.org/10.12740/PP/ONLINEFIRST/115208.

Article  PubMed  Google Scholar 

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621. https://doi.org/10.1124/PR.117.015198.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4. https://doi.org/10.1016/S0006-3223(99)00230-9.

Article  CAS  PubMed  Google Scholar 

Alnefeesi Y, Chen-Li D, Krane E, Jawad MY, Rodrigues NB, Ceban F, Di Vincenzo JD, Meshkat S, Ho RCM, Gill H, et al. Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis. J Psychiatr Res. 2022;151:693–709. https://doi.org/10.1016/J.JPSYCHIRES.2022.04.037.

Article  PubMed  Google Scholar 

Terao I, Tsuge T, Endo K, Kodama W. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2024;346:49–56. https://doi.org/10.1016/J.JAD.2023.11.023.

Article  CAS  PubMed  Google Scholar 

Seshadri A, Prokop LJ, Singh B. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for major depression: a systematic review and meta-analysis. J Affect Disord. 2024;356:379–84. https://doi.org/10.1016/J.JAD.2024.03.137.

Article  CAS  PubMed  Google Scholar 

Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — first FDA-approved antidepressant in a new class. N Engl J Med. 2019;381:1–4. https://doi.org/10.1056/NEJMP1903305/SUPPL_FILE/NEJMP1903305_DISCLOSURES.PDF.

Article  PubMed  Google Scholar 

Gałecki P, Bliźniewska-Kowalska K, Cubała WJ, Depukat A, Mosiołek A, Rybakowski J, Samochowiec J, Sobolewski B, Szulc A, Dudek D. Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a working group appointed by the national consultant in the field of psychiatry. Psychiatr Pol. 2024;58:377–401. https://doi.org/10.12740/PP/189494.

Article  PubMed  Google Scholar 

von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. https://doi.org/10.1016/J.ECLINM.2022.101809.

Article  Google Scholar 

Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11. https://doi.org/10.1056/NEJMOA2032994.

Article  CAS  PubMed  Google Scholar 

Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48. https://doi.org/10.1056/NEJMOA2206443.

Article  CAS  PubMed  Google Scholar 

Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843–53. https://doi.org/10.1001/JAMA.2023.14530.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Metaxa AM, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385:e078084. https://doi.org/10.1136/BMJ-2023-078084.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z, Wu Q, Wang Q, Ö K, Professor A. Effect of celecoxib on improving depression: a systematic review and meta-analysis. World J Clin Cases 2022;10:7872.

Bavaresco DV, Uggioni MLR, Ferraz SD, Marques RMM, Simon CS, Dagostin VS, Grande AJ, da Rosa MI. Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis. Pharmacol Biochem Behav. 2020;188:172838. https://doi.org/10.1016/J.PBB.2019.172838.

Article  CAS  PubMed  Google Scholar 

Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. 2012;169:1238–1244. https://doi.org/10.1176/APPI.AJP.2012.12050648.

Tess AV, Smetana GW. Medical evaluation of patients undergoing electroconvulsive therapy. N Engl J Med. 2009;360:1437–44. https://doi.org/10.1056/NEJMRA0707755.

Article  CAS  PubMed  Google Scholar 

Zandi PP, Morreale M, Reti IM, Maixner DF, McDonald WM, Patel PD, Achtyes E, Bhati MT, Carr BR, Conroy SK, et al. National Network of Depression Centers’ recommendations on harmonizing clinical documentation of electroconvulsive therapy. J ECT. 2022;38:159–64. https://doi.org/10.1097/YCT.0000000000000840.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ross EL, Zivin K, Maixner DF. Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the United States. JAMA Psychiat. 2018;75:713. https://doi.org/10.1001/JAMAPSYCHIATRY.2018.0768.

Article  Google Scholar 

Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiat. 2017;74:9–10. https://doi.org/10.1001/JAMAPSYCHIATRY.2016.2586.

Article  Google Scholar 

Heijnen WT, Birkenhäger TK, Wierdsma AI, Van Den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol. 2010;30:616–9. https://doi.org/10.1097/JCP.0B013E3181EE0F5F.

Article  PubMed  Google Scholar 

Lemasson M, Rochette L, Galvão F, Poulet E, Lacroix A, Lecompte M, Auriacombe M, Patry S, Haesebaert F. Pertinence of titration and age-based dosing methods for electroconvulsive therapy: an international retrospective multicenter study. J ECT. 2018;34:220–6. https://doi.org/10.1097/YCT.0000000000000508.

Article  PubMed  Google Scholar 

Peterchev AV, Krystal AD, Rosa MA, Lisanby SH. Individualized low-amplitude seizure therapy: minimizing current for electroconvulsive therapy and magnetic seizure therapy. Neuropsychopharmacology. 2015;40:2076. https://doi.org/10.1038/NPP.2015.122.

Article  PubMed  PubMed Central  Google Scholar 

Sackeim HA, Prudic J, Nobler MS, Fitzsimons L, Lisanby SH, Payne N, Berman RM, Brakemeier EL, Perera T, Devanand DP. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul. 2008;1:71. https://doi.org/10.1016/J.BRS.2008.03.001.

Article  PubMed  PubMed Central  Google Scholar 

Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, Fitzsimons L, Moody BJ, Clark J. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57:425–34. https://doi.org/10.1001/ARCHPSYC.57.5.425.

Article  CAS  PubMed  Google Scholar 

Steele JD, Farnan T, Semple DM, Bai S. Fronto-medial electrode placement for electroconvulsive treatment of depression. Front Neurosci. 2022;16:1029683. https://doi.org/10.3389/FNINS.2022.1029683.

Article  PubMed  PubMed Central  Google Scholar 

Youssef NA, McCall WV, Ravilla D, McCloud L, Rosenquist PB. 2020) Double-blinded randomized pilot clinical trial comparing cognitive side effects of standard ultra-brief right unilateral ECT to 0.5 a low amplitude seizure therapy (LAP-ST. Brain Sci. 2020;10:1–10. https://doi.org/10.3390/BRAINSCI10120979.